Back to top
more

Eton Pharmaceuticals (ETON)

(Delayed Data from NSDQ)

$8.62 USD

8.62
94,034

+0.15 (1.77%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 170.51% and 10.32%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

5 Under-$15 Stocks Wall Street Analysts Recommend Buying

by Sanghamitra Saha

After a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT).

Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

by Zacks Equity Research

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

by Zacks Equity Research

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook

by Zacks Equity Research

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.

Viatris (VTRS) to Divest Some More Businesses, Shares Gain

by Zacks Equity Research

Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.

Novartis (NVS) Announces Positive Data on Kidney Disease Drug

by Zacks Equity Research

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024

by Zacks Equity Research

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

by Zacks Equity Research

Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

by Zacks Equity Research

Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

by Zacks Equity Research

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study

by Zacks Equity Research

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

by Zacks Equity Research

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy

by Zacks Equity Research

Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.

ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray

by Zacks Equity Research

ARS Pharmaceuticals, Inc. (SPRY) plunges on a surprise CRL by the FDA for its nasal spray curated for allergic reactions.

Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Encompass Health (EHC) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.

Novartis' (NVS) Shareholders Approve Sandoz Separation

by Zacks Equity Research

Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.

Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico

by Zacks Equity Research

Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.

Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON)

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.